Johnson & Johnson (NYSE:JNJ)’s Lung Cancer Initiative has signed a licensing and development accord to access narrow-spectrum Kinase inhibitors of Pulmatrix Inc (NASDAQ:PULM). As per the terms of the deal, Lung Cancer Initiative will initially pay an upfront amount of $7.2 million to Pulmatrix. The company will pay an additional amount of $2 million on […]
Ted Raad
Recent Posts
Winners Creates Another New Expected Revenue Stream – Signs Terms Sheet With “Horse Races Now” and “Next Play Digital”
Human Capital Management: The Key to Building a Successful Public Sector Workforce
FUTURIS COMPANY (FTRS) HIRES ROBERT DAY AS NEW CFO TO BECOME A FULLY REPORTING COMPANY
Greene Concepts Secures New Retail Distribution to Five Hundred Grocery Stores
Code Green Apparel (CGAC) Provides Shareholder Update Following Change in Control, Acquisition of Bitcoin Mining Assets and “Shell Company” Status Upgrade
Popular Post
-
InnerScope Hearing Technologies (OTC: INND) Launches HearingAssist Brand of FDA-Registered OTC Rechargeable Hearing Aids on Target.com
-
Sports Gambling and the Horse Racing Market
-
ZICIX+CTIP-FII RECEIVES NOTICE TO PROCEED FROM PROJECT OWNER TO START THE $20 MILLION SENIOR CITIZENS RESIDENCE PROJECT IN NEWARK, NEW JERSEY
-
Principal Solar to Acquire Minerva-Rockdale Leases, Wells, and Assets
-
Kona Gold Beverage, Inc Announces its Ooh La Lemin Lemonades to be sold in Town Pump Convenience Stores in Montana
